Intriguingly, however, CYP27A1 or exogenous 27HC treatment in the ovarian cancer mouse model has also been shown to augment peritoneal tumor spread and carboplatin resistance, consistent with Kaplan–Meier analyses of CYP27A1 in ovarian cancer patients (24). This evidence concerns the gene CYP27A1 and ovarian carcinoma.